Swedbank AB Buys 6,300 Shares of Icon Plc $ICLR

Swedbank AB lifted its stake in Icon Plc (NASDAQ:ICLR) by 15.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 48,100 shares of the medical research company’s stock after purchasing an additional 6,300 shares during the period. Swedbank AB owned 0.06% of Icon worth $8,418,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of ICLR. BayBridge Capital Group LLC bought a new position in Icon in the third quarter worth about $244,000. DAVENPORT & Co LLC grew its holdings in shares of Icon by 15.1% during the 3rd quarter. DAVENPORT & Co LLC now owns 3,194 shares of the medical research company’s stock worth $559,000 after acquiring an additional 420 shares during the period. Net Worth Advisory Group grew its holdings in shares of Icon by 79.8% during the 3rd quarter. Net Worth Advisory Group now owns 3,563 shares of the medical research company’s stock worth $624,000 after acquiring an additional 1,581 shares during the period. Confluence Investment Management LLC raised its position in shares of Icon by 13.5% in the 3rd quarter. Confluence Investment Management LLC now owns 4,689 shares of the medical research company’s stock worth $821,000 after acquiring an additional 557 shares in the last quarter. Finally, Foster Victor Wealth Advisors LLC purchased a new position in shares of Icon in the 3rd quarter valued at approximately $219,000. Institutional investors own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Rothschild Redb upgraded Icon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 3rd. Robert W. Baird set a $220.00 target price on shares of Icon in a research report on Friday, October 24th. Zacks Research raised shares of Icon from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 25th. Bank of America lowered shares of Icon from a “buy” rating to a “neutral” rating and set a $195.00 price objective on the stock. in a research note on Monday, December 15th. Finally, BMO Capital Markets started coverage on shares of Icon in a research note on Thursday, November 13th. They set a “market perform” rating and a $175.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and eleven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Icon currently has an average rating of “Moderate Buy” and a consensus price target of $205.31.

Icon Stock Performance

Shares of ICLR stock opened at $182.84 on Friday. The company has a market capitalization of $14.77 billion, a price-to-earnings ratio of 24.74, a price-to-earnings-growth ratio of 3.39 and a beta of 1.25. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. Icon Plc has a one year low of $125.10 and a one year high of $228.29. The company’s 50-day moving average is $175.36 and its 200 day moving average is $169.89.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.